Cullinan Oncology
CGEM

$20.16

2.16%

Market Cap: 1.16B

About: Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.

Employees: 85

Healthcare Biological Products, Except Diagnostic Substances

Funds holding %

of 6,702 funds

Analysts bullish %

of 10 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

79% more capital invested

Capital invested by funds: $376M [Q4 2023] → $671M (+$295M) [Q1 2024]

36% more call options, than puts

Call options by funds: $215K | Put options by funds: $158K

11% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 37

5.26% more ownership

Funds ownership: 86.16% [Q4 2023] → 91.42% (+5.26%) [Q1 2024]

0% more funds holding

Funds holding: 113 [Q4 2023] → 113 (+0) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q4 2023] → 3 (+0) [Q1 2024]

0% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 19

See Fund Rankings

Research analyst outlook

10 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$26

29%

upside

Avg. target

$31

53%

upside

High target

$40

98%

upside

10 analyst ratings

10 positive

100%

0 neutral

0 negative

HC Wainwright & Co. Edward White	39%upside $28	Buy Reiterated	3 Jun 2024
HC Wainwright & Co. Edward White	39%upside $28	Buy Reiterated	24 May 2024
HC Wainwright & Co. Edward White	39%upside $28	Buy Maintained	16 May 2024
Wedbush Robert Driscoll	79%upside $36	Outperform Reiterated	16 May 2024
Stifel Bradley Canino	98%upside $40	Buy Initiated	1 May 2024

See Analyst Rankings

Financial journalist opinion

Neutral

GlobeNewsWire

1 month ago

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had progressed after prior amivantamab treatment Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had progressed after prior amivantamab treatment

Neutral

GlobeNewsWire

2 months ago

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer and Jeffrey Jones, MD, MBA, Chief Medical Officer, will participate in a fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA, being held virtually on May 28 and 29, 2024.

Neutral

GlobeNewsWire

2 months ago

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung cancer (NSCLC) with oncogenic mutations

Neutral

GlobeNewsWire

2 months ago

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at ASCO 2024 Annual Meeting

Neutral

GlobeNewsWire

2 months ago

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment of Mary Kay Fenton as Chief Financial Officer, beginning April 29.

Neutral

GlobeNewsWire

3 months ago

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid tumors will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31-June 4, 2024. The data will include first results from the dose escalation cohort of CLN-619 in combination with checkpoint inhibitor pembrolizumab and updated results from the monotherapy dose escalation cohort in patients with advanced solid tumors.

Neutral

GlobeNewsWire

3 months ago

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication

Neutral

GlobeNewsWire

3 months ago

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

Financing includes new and existing leading life sciences institutional investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 Cullinan to host a virtual investor event on April 16 at 8:00 am ET CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (formerly Cullinan Oncology, Inc.) (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that it has entered into a stock purchase agreement with certain institutional and accredited investors for a private placement of approximately $274.0 million of shares of its common stock at a price of $19.00 per share and, in lieu of common stock to certain investors, $6.0 million of pre-funded warrants to purchase shares of its common stock at a price of $18.999 per pre-funded warrant.

Neutral

GlobeNewsWire

4 months ago

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Cullinan remains on track to report additional solid tumor dose escalation data for CLN-619 in the second quarter of 2024 and recently received FDA clearance for an IND to evaluate CLN-619 in relapsed/refractory multiple myeloma

Neutral

GlobeNewsWire

4 months ago

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

Company will initiate Phase 1 study of CLN-619 for relapsed or refractory multiple myeloma, first MICA/B antibody clinical study in hematologic malignancies

$Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma$

See News Rankings

Cullinan OncologyCGEM

Fund manager confidence

79% more capital invested

36% more call options, than puts

11% more repeat investments, than reductions

5.26% more ownership

0% more funds holding

0% more funds holding in top 10

0% more first-time investments, than exits

Research analyst outlook

10 analyst ratings

Financial journalist opinion

Cullinan Oncology
CGEM